7683-59-2 Usage
Description
Isoproterenol is a sympathomimetic drug with high selectivity to β-adrenoreceptors. It is characterized by the addition of a bulky iso-propyl or tert-butyl group at the nitrogen atom of the β-phenylethylamino skeleton, which is associated with higher affinity to β-adrenergic receptive regions than to α-adrenergic. Isoproterenol is devoid of significant α-adrenergic agonistic action. Activation of β1-adrenergic receptors in the heart increases positive chronotropic and ionotropic action. Peripheral vascular resistance is increased by the widening of blood vessels, primarily in skeletal muscle, but also in renal and mesenteric blood circulation, which is caused by the β2-adrenergic system.
Uses
Used in Respiratory Conditions:
Isoproterenol is used as a bronchodilator for bronchospasms and asthma, helping to relax and widen the airways for easier breathing.
Used in Cardiac Conditions:
Isoproterenol is used as a treatment for cardiac block and shock, improving heart function and circulation by activating β1-adrenergic receptors.
Used in Emergency Medicine:
Isoprenaline, a potent β-agonist primarily acting at the β1-receptor, is used for the temporary emergency treatment of bradyarrhythmias. Its β2 effects lead to bronchoand vasodilatation, with a decrease in systemic vascular resistance (SVR). It is only available in the UK via specialist importing companies and is administered by intravenous infusion at a dose range of 0.5–20 μg min–1.
Indications
Isoproterenol is administered almost exclusively by
inhalation from metered-dose inhalers or from nebulizers.
The response to inhaled isoproterenol and other inhaled
adrenomimetics is instantaneous. The action of
isoproterenol is short-lived, although an objective
measurement of pulmonary function has shown an effective
duration of up to 3 hours. When it is administered
by inhalation, the cardiac effects of isoproterenol
are relatively mild, although in some cases a substantial
increase in heart rate occurs.
World Health Organization (WHO)
Isoprenaline, a beta-adrenoreceptor agonist, was introduced in
1949 as treatment for a number of cardiac disorders and as a bronchial dilator for
the symptomatic treatment of asthma. There is evidence that regular inhalation of
bronchodilator drugs is associated, in some cases with exacerbation of the
disease and with increased fatality rates. The underlying causes are disputed, but
an increasing body of opinion now advocates regular maintenance therapy with
inhaled, corticosteroids coupled with supplementary use as required of bronchial
drugs to suppress exacerbations.
Clinical Use
The cardiac stimulation caused by its 1-activity andits lack of oral activity have led to its diminished use infavor of more selective -agonists. The problems have beenovercome at least partially by the design and developmentof several noncatechol selective 2-agonists. These agentsrelax smooth muscle of the bronchi, uterus, and skeletalmuscle vascular supply. They find their primary use as bronchodilatorsin the treatment of acute and chronic bronchialasthma and other obstructive pulmonary diseases.
Clinical Use
Isoproterenol is used principally by inhalation for
the management of bronchospasm. It is also used intravenously
for asthma and as a stimulant in cardiac arrest.
Safety Profile
Poison by ingestion,
subcutaneous, intravenous, and
intraperitoneal routes. An experimental
teratogen. Other experimental reproductive
effects. Human systemic effects by
intramuscular route: increased pulse and
cardac rate. A bronchodilator. Mutation
data reported. When heated to
decomposition it emits toxic fumes of NOx
Synthesis
Isoproterenol, 1-(3,4-dihydroxyphenyl)-2-iso-propylaminoethanol (11.1.8),
is synthesized by an analogous scheme of making epinephrine. Interaction of ω-chloro-3,4-
dihydroxyacetophenone (chloroacetylpyrocatechol) with isopropylamine gives ω-isopropylamino-3,4-dihydroxyacetophenone (11.1.7), reduction of the carbonyl group of which by
hydrogen using a palladium on carbon catalyst gives isoproterenol (11.1.8) [11,12].
Check Digit Verification of cas no
The CAS Registry Mumber 7683-59-2 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 7,6,8 and 3 respectively; the second part has 2 digits, 5 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 7683-59:
(6*7)+(5*6)+(4*8)+(3*3)+(2*5)+(1*9)=132
132 % 10 = 2
So 7683-59-2 is a valid CAS Registry Number.
InChI:InChI=1/C11H17NO3/c1-7(2)12-6-11(15)8-3-4-9(13)10(14)5-8/h3-5,7,11-15H,6H2,1-2H3
7683-59-2Relevant articles and documents
1,4-dihydropyridine derivative with a guaiacoxypropanolamine and/or phenoxypropanolamine moiety
-
, (2008/06/13)
The invention disclosed some 1,4-dihydropiridine derivative chemically with guaiacoxypropanolamine based phenoxypropanolamine moiety and pharmacologically with β-adrenoceptor blocking and partial β2-agonist activities, is now emerging. The compound of 1,4-dihydropiridine derivative wherein has the formula I, wherein R selected from four group as follow R1 selected from X, H, NO2 saturated C1-C6 alkyl chain, unsaturated C6-C6 alkyl chain, R2 selected from H, CH3 R3 and R4 are individually selected from saturated C1-C6 alkyl chain, unsaturated C1-C6 alkyl chain; R5 selected from OH, saturated C1-C6 alkyl chain, unsaturated C1-C6 alkyl chain.
Antiinflammatory salts of piroxicam
-
, (2008/06/13)
Improved antiinflammatory salts of piroxicam with antidepressant doxepin, with bronchodilator pirbuterol or isoproterenol, with H2 -antagonist inhibitor 2-guanidino-4-(2-methyl-4-imidazolyl)thiazole, with pyridoxine, a member of the vitamin B6 complex, or with antihypertensive trimazosin.
